Equities
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)1.58
  • Today's Change0.09 / 6.04%
  • Shares traded1.50m
  • 1 Year change+46.30%
  • Beta1.6257
Data delayed at least 15 minutes, as of Feb 13 2026 06:37 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Brii Biosciences Ltd is a biotechnology company primarily engaged in the development of therapies for infectious diseases and central nervous system diseases. The Company's main products include BRII-179, a candidate drug for hepatitis B virus (HBV) immunotherapy, Tobevibart, an investigational neutralizing monoclonal antibody targeting hepatitis B surface antigen (HBsAg), as well as soralimixin (BRII-693), a synthetic lipopeptide for treating multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative bacterial infections. The Company primarily operates its businesses in the domestic market.

  • Revenue in HKD (TTM)0.00
  • Net income in HKD-425.01m
  • Incorporated2017
  • Employees96.00
  • Location
    Brii Biosciences Ltd3rd Floor, Building 7Zhongguancun Dongsheng, InternationalNo. 1 North Yongtaizhuang Road, HaidianBEIJING 100192ChinaCHN
  • Websitehttps://www.briibio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sirnaomics Ltd13.90m-109.57m739.83m52.00------53.23-1.33-1.330.161-0.38050.0637----201,447.40-36.30-80.21-216.85-100.4967.44---570.30-27,838.86---8.20--------34.70---38.10--
JW (Cayman) Therapeutics Co Ltd201.03m-698.50m962.05m292.00--0.9357--4.79-1.68-1.680.48452.470.10461.349.59715,393.00-36.34-35.14-47.41-39.0655.52---347.47-898.771.45-1,808.420.2907---8.99--23.10---32.98--
Sunho Biologics Inc0.00-92.84m1.00bn128.00--1.84-----0.6152-0.61520.003.470.00----0.00-14.33---15.84----------6.57--0.1242------39.74------
Brii Biosciences Ltd0.00-424.89m1.08bn96.00--0.3813-----0.5837-0.58370.003.910.00----0.00-14.05-49.92-14.09-54.57-------12,750.27----0.003---100.00---190.66---33.13--
B&K Corp Ltd295.18k-206.53m1.12bn100.00--11.69--3,786.68-1.76-1.760.00250.8126----------------92.34---69,968.59------0.0371---44.70---101.78------
Kintor Pharmaceutical Ltd12.42m-188.94m1.39bn136.00--5.11--112.00-0.4368-0.43680.02870.54590.019410.661.0673,942.66-29.53-47.72-44.54-55.96-55.12-36.16-1,521.00-8,974.730.4222-33.760.2881------85.36---53.11--
Wuhan YZY Biopharma Co Ltd163.99m-88.26m1.40bn106.00------8.56-0.4553-0.45530.846-0.16010.580511.5413.961,451,221.00-31.24---133.35--63.96---53.82--0.9019-24.381.21------49.09------
HighTide Therapeutics Inc0.00-329.29m1.47bn57.00--3.72-----0.7283-0.72830.000.69320.00----0.00-49.50---63.55--------------0.2129------59.35------
Immunotech Biopharm Ltd0.00-252.77m1.59bn173.00---------0.4516-0.45160.00-0.28780.00----0.00-37.04-36.20-186.73-45.67--------0.0712-6.631.48------44.18--5.95--
ImmuneOnco Biopharmaceuticls Shanghi Inc126.78m-342.32m1.91bn195.00--2.98--15.08-0.8702-0.87020.3221.480.148--3,865.48812,682.70-40.09---51.56-------270.79------0.2236--19,109.59--16.76------
Cloudbreak Pharma Inc78.18m-327.04m1.94bn60.00------24.79-0.3899-0.38990.0932-3.08------1,532,882.00-------------418.33------19.44------23.40------
Mabpharm Ltd479.44m-31.08m2.10bn383.00--18.8157.054.39-0.0075-0.00750.11630.02710.42090.46594.051,522,038.00-2.73-19.62-4.02-25.6986.40---6.48-211.590.6906-1.580.7552--196.27--38.89---12.13--
Data as of Feb 13 2026. Currency figures normalised to Brii Biosciences Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

0.30%Per cent of shares held by top holders
HolderShares% Held
American Century Investment Management, Inc.as of 08 Jan 2026750.50k0.10%
SSgA Funds Management, Inc.as of 08 Jan 2026581.50k0.08%
Dimensional Fund Advisors LPas of 30 Nov 2025364.00k0.05%
Allianz Global Investors Asia Pacific Ltd.as of 30 Jun 2025322.50k0.04%
Acadian Asset Management LLCas of 30 Sep 2025128.37k0.02%
UBS Asset Management (Hong Kong) Ltd.as of 30 Jun 202226.50k0.00%
DFA Australia Ltd.as of 30 Nov 20251.29k0.00%
Dimensional Fund Advisors Ltd.as of 30 Nov 202588.000.00%
GF Fund Management Co., Ltd.as of 30 Jun 20250.000.00%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.